Price (delayed)
$165.8
Market cap
$4.78B
P/E Ratio
53.14
Dividend/share
N/A
EPS
$3.12
Enterprise value
$4.44B
Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.
There are no recent dividends present for KRYS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.